Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Those were the days

As if any of us needed a reminder of how times have changed, Regeneron Pharmaceuticals Inc.'s stock price history serves as a benchmark of the way things were and the way they are.

Considered pricey even in the halcyon days of April 1991, REGN went public at $22, selling 4.5 million shares and raising $99 million. That works out to a $239 million pre-money valuation and

Read the full 651 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers